Agenus to Present at Two Upcoming Healthcare Conferences


Agenus to Present at Two Upcoming Healthcare Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (NAS: AGEN) , a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will present a corporate overview at two upcoming conferences. Dr. Garo Armen, chairman and CEO of Agenus, will present at the 15th Annual Rodman & Renshaw Healthcare Conference on September 10, 2013 at 10:25 am Eastern time at the Millennium Broadway Hotel in New York City, NY. Dr. Armen will also present at the Stifel Healthcare Conference 2013 at 10:20 am Eastern time on September 11, 2013 at the Four Seasons Hotel in Boston, MA.

Web Cast Information

The live and archived webcast of the company presentation will be accessible from the company's website at Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Agenus website for one month following the conference.

About Agenus

Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, please visit

Media and Investor Contact:
Agenus Inc.
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations and
Corporate Communications

KEYWORDS: United States North America Massachusetts New York


The article Agenus to Present at Two Upcoming Healthcare Conferences originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.